Combining activatable nanodelivery with immunotherapy in a murine breast cancer model.

ABSTRACT: A successful chemotherapy-immunotherapy solid-tumor protocol should accomplish the following goals: debulk large tumors, release tumor antigen for cross-presentation and cross-priming, release cancer-suppressive cytokines and enhance anti-tumor immune cell populations. Thermally-activated drug delivery particles have the potential to synergize with immunotherapeutics to accomplish these goals; activation can release chemotherapy within bulky solid tumors and can enhance response when combined with immunotherapy. We set out to determine whether a single protocol, combining locally-activated chemotherapy and agonist immunotherapy, could accomplish these goals and yield a potentially translational therapy. For effective delivery of free doxorubicin to tumors with minimal toxicity, we stabiliz

SUBMITTER: Kheirolomoom A 

PROVIDER: S-EPMC6660242 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature